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Classification of stomach cancer by conventional patho-
logical criteria has not helped in the assessment of prognosis
of this tumour (Morson et al., 1990) and the availability of
new markers that could be applied to routinely-processed
pathologic material would be of great value. Recent studies
have demonstrated that assessment of gene copy number and
expression levels of the receptor tyrosine kinase oncogenes
encoding the EGF receptor (also known as c-erbB) and
c-erbB-2 (also known as HER2 or neu) can offer useful
information for the prediction of prognosis in several com-
mon human cancers, such as breast cancer and ovarian
cancer. In stomach cancer, amplification or overexpression of
c-erbB-2 has been reported in 19-40% of cases (Tal et al.,
1988; Yokota et al., 1988; Park et al., 1989; Oda et al., 1990;
Gutman et al., 1989; Falck & Gullick, 1989; Houldsworth et
al., 1990) but only one study has so far examined the
concordance between level of expression of this oncogene
determined by immunohistochemistry in routinely-processed
pathology specimens and gene copy number determined by
Southern blotting (Houldsworth et al., 1990). Until recently,
antibodies which reliably detect EGF receptor expression in
fixed and paraffin-embedded pathological material have not
been available, limiting the study of receptor protein expres-
sion. Overexpression of EGF receptors has been detected in
frozen samples of gastric adenocarcinoma at a frequency of
up to 35% in advanced disease (Yasui et al., 1988a; b).
However, amplification of the EGF receptor gene appears to
be uncommon in stomach cancer (Yoshida et al., 1989). We
set out to determine the frequency of EGF receptor and
c-erbB-2 gene amplification and rearrangement by Southern
blotting, and to survey the expression of each of these proto-
oncogenes by immunohistochemistry in a parallel series of
frozen and routinely-fixed paraffin-embedded gastric cancer
specimens.
Gastrectomy specimens were examined by a pathologist
immediately after resection and samples of cancer (confirmed
on frozen section) were excised, snap-frozen in liquid nitro-
gen and stored below -70'C until required. The remainder
of each specimen was then fixed in formalin or Bouin's
fixative and processed for embedding in paraffin blocks. Peri-
pheral blood samples were taken from each patient and the
white cell fraction kept frozen below -70°C until required.
High molecular weight DNA was extracted from tumour
samples and, in 30 out of the total of 40 cases, a paired
sample of peripheral blood leucocytes using a Model 340A
Nucleic Acid Extractor from Applied Biosystems, EcoRI-
digested DNA (10gg) was electrophoresed in 0.8% agarose
gels and transferred to Hybond-N filters (Amersham). Hybri-
disation and washing were carried as recommended by the
manufacturer. Hybridisation probes used to detect proto-
oncogene sequences were, for detection of the EGF receptor
gene, a 1.8 kb EcoRI purified fragment of p64.1 (Ullrich et
al., 1984) and for detection of c-erbB-2, a 3.25 kb HindlII/
KpnI fragment of pSV2erbB-2 which contains the complete
cDNA of c-erbB-2 (Yamamoto et al., 1986). The blots were
stripped and then rehydridised with a 1.8 kb PstI fragment of
beta-actin (Cleveland et al., 1980) to control for loading
differences between samples.
Signal intensity on autoradiographs was quantitated using
an Ultroscan XL laser densitometer (LKB).
Polymerase chain reaction (PCR) amplification and oligo-
nucleotide probing for transmembrane mutations of the
c-erbB-2 proto-oncogene was carried out using oligonucleo-
tides and protocols as previously described (Lemoine et al.,
1990a).
To detect c-erbB-2 immunoreactivity in frozen and paraffin
sections an affinity-purified preparation of rabbit antibody
21N (Gullick et al., 1987) was used at a concentration of
2.6 jig ml-'. This reagent has been well characterised and
widely used for immunohistochemical detection of c-erbB-2
in tissue sections (Gusterson et al., 1988). To detect EGF
receptor immunoreactivity in frozen and paraffin sections an
affinity-purified preparation of the rabbit antibody 12E
(raised against a synthetic peptide representing residues 1059
to 1072 in the cytoplasmic domain of EGF receptor, Gullick
et al., 1985) was used at a concentration of 4 gg ml-', as well
as an affinity-purified preparation of the rabbit antibody 14E
(raised against a synthetic peptide of residues 1164 to 1176 of
EGF receptor, Gullick et al., 1985) at 4 Lgml'. The mono-
clonal antibody EGFR1 (raised against A431 cells and recog-
nises the native folded external domain of EGF receptor,
Waterfield et al., 1982; has been extensively characterised for
use in immunohistochemistry, Gullick et al., 1986) was used
at a concentration of 10LIg ml-' to detect EGF receptor
immunoreactivity in frozen sections only.
Paraffin sections were rehydrated by passage through xylene
and graded alcohols to phosphate-buffered saline. Endo-
geneous peroxidase activity was quenched by incubation in
0.3% hydrogen peroxide for 30min and then rinsing in dis-
tilled water. For frozen sections endogenous peroxidase
activity was quenched by incubation in 0.1% phenylhydrazine
hydrochloride for 5 min and then rinsing in distilled water.
The immunohistochemical technique involved the sequential
application of the following reagents: the primary antibody
(21N, 12E, 14E or EGFR1) at the concentration stated
above for 1 h at room temperature, a secondary biotinylated
anti-rabbit (for 21N, 12E and 14E) or anti-mouse (for
EGFR1) antibody (DAKOPATTS) diluted 1:500 for 30 min,
and ABComplex/HRP (DAKOPATTS) for 30 min. Each
incubation was followed by rinsing the tissue sections in
phosphate-buffered saline three times (5 min each). The sites
of immunoprecipitate were identified by light microscopy
following treatment with a chromogen, 3,3'-diaminobenzi-
dine. No special treatments of the section were required for
use of these antibodies. A standard avidin-biotin-peroxidase
complex method was used as previously described (Falck &
Gullick, 1989). Specificity of the antibodies was tested by loss
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of staining after pre-absorption of antibody with the immu-
nising peptide, and retention of staining after pre-absorption
with other non-specific peptides. Overexpression of the
growth factor receptor (EGF receptor or c-erbB-2) is defined
as staining of tumour cell membranes, often accompanied by
cytoplasmic staining. As detailed below, such immunoreac-
tivity was not observed on cell membranes in normal
stomach mucosa.
The results of tumour analysis are presented in Tables I
and II. In the normal stomach very faint cytoplasmic
immunoreactivity of EGF receptor was observed only in the
parietal cells of the gastric glands when using the 12E anti-
body. With all of the anti-EGF receptor antibodies there was
strong staining of the brush border of surface enterocytes of
the normal small intestine and in intestinal metaplasia of the
stomach (Figure 2b). Immunoreactivity for c-erbB-2 was not
detected in non-neoplastic stomach with the antibody 21N at
the concentration used.
In the tumour series, overexpression of the c-erbB-2
growth factor receptor proto-oncogene (recognised as stain-
ing of tumour cell membranes) was detected in 26% of all
the cases examined in paraffin section, more frequently in the
intestinal type (53%) than in diffuse type (8%). There was no
apparent association with tumour stage or lymph node in-
volvement, nor with tumour site or growth pattern (expand-
ing/infiltrative). Southern blot analysis revealed four cases of
c-erbB-2 gene amplification (Figure la) which represents a
frequency of 13% in the 30 cases examined. Three of these
cases were classified as intestinal type tumours and one as
diffuse type by the Lauren classification. Strong membrane
immunoreactivity with the 21N antiserum was demonstrable
in both frozen sections and paraffin sections, usually with
more than 80% of the tumour cells positive in these gene-
amplified cases (Table II). In four other cases, the c-erbB-2
gene was present in apparently single copy on Southern blot
analysis and there was moderate to strong membrane
immunoreactivity just in some areas of the tumour sections.
Two cases (omitted from Table II for clarity) were not
examined by Southern blot, but had focal 21N immunore-
activity (less than 5% of tumour cells positive). The failure to
identify immunoreactivity in frozen sections of some tumours
in which there was definite positivity in paraffin sections
could be due to the patchy nature of overexpression of
c-erbB-2 in cases without gene amplification. The sensitivity
of immunohistochemical detection of c-erbB-2 overexpression
appears to be at least as good in paraffin sections as in frozen
sections in this series. However, other authors have shown
that, at least in breast cancer, low levels of c-erbB-2 immuno-
reactivity detectable in frozen material may not survive
exposure to fixation and processing for paraffin embedding
(Slamon et al., 1989).
Oligonucleotide probing of PCR-amplified genomic DNA
did not detect any evidence of potentially activating muta-
tions in the transmembrane region of the c-erbB-2 oncogenes
in 31 cases examined. This is consistent with the absence of
this potential mechanism of activation in other human
Table II Extent of immunoreactivity in cases of EGFR or c-erbB-2
overexpression
EGF receptor c-erbB-2
Immunoreactivit/a Gene Single Gene Single
in paraffin amplification copy amplification copy
section (n=2) (n = 7) (n = 4) (n=4)
Uniform 1 3
(>80% tumour)
Patchy 6 1 1
(20-80% tumour)
Patchy 2
(5-20% tumour)
Focal 1 1
(<5% tumour)
Negative
aImmunoreactivity here refers to definite staining ofthe tumour cell
membranes, which was usually accompanied by some cytoplasmic
staining. Cases in which there was only cytoplasmic staining are not
included here.
cancers we have examined including 100 breast cancers, 60
thyroid tumours, 23 pancreatic cancers and 32 brain tumours
(Lemoine et al., 1990a, b; Hall et al., 1990; Tuzi et al., 1991).
Overexpression of EGF receptor (recognised as staining of
tumour cell membranes often accompanied by cytoplasmic
staining) was detected in 18% ofgastric cancers examined by
immunohistochemistry on paraffin sections and, as for
c-erbB-2, was more frequent in intestinal type tumours (27%)
than in diffuse type tumours (12%). There was no apparent
association with tumour stage or lymph node involvement,
nor with tumour site or growth pattern (expanding/infil-
trative). Southern blot analysis revealed two cases (cases 4
and 5 illustrated in Figure lb) of EGF receptor gene ampli-
fication out of 30 cases analysed, but only in one of these
was overexpression demonstrable as uniform (>80% of the
tumour positive) membrane immunoreactivity with the 12E
and 14E antibodies in frozen and paraffin sections (Figure
2a), and the EGFR1 antibody in frozen sections. The explan-
ation for our failure to demonstrate overexpression in the
other case is presently unknown. There were seven cases of
EGF receptor overexpression in the absence of gene ampli-
fication, but in these cases the immunoreactivity was not
uniform and some areas of the tumours were completely
negative. The immunoreactivity for EGF receptor in these
cases was demonstrable with all of the antibodies used in
frozen section, but while the EGFR1 and 12E antibodies
gave comparable results in the detection of membrane ex-
pression, the 14E antibody gave consistently weaker staining
and often showed cytoplasmic rather than membrane localis-
ation in the tumour cells. The sensitivity of immunohisto-
chemical detection of EGF receptor overexpression using the
12E antiserum was higher in paraffin sections than in frozen
sections of this series of stomach cancers. This is at least
partly accounted for by the greater ease of interpretation of
EGF receptor immunoreactivity, often accentuated at the
Table I Frequency ofabnormalitiesa of EGF receptor and c-erbB-2 in human gastric cancers
WHO classification
Lauren classification Well/moderately Poorly
differentiated differentiated Signet ringl
Intestinal Diffuse tubular/papillary tubular/papillary mucoid Undifferentiated
EGFR
Frozen sections 3/16 (19%) 2/24 (8%) 3/16 (19%) 2/19 (11%) 0/4 0/1
Paraffin sections 4/15 (27%) 3/24 (12%) 4/16 (25%) 3/19 (16%) 0/4 0/1
Gene amplification 1 case, >20 fold 1 case, >20 fold I case, >20 fold 1 case, >20 fold
c-erbB-2
Frozen sections 6/16 (38%) 1/24 (4%) 4/16 (25%) 1/19 (5%) 2/4 0/1
Paraffin sections 8/15 (53%) 2/24 (8%) 5/16 (31%) 3/19 (16%) 2/4 0/1
Gene amplification 1 case, 5-10 fold 1 case, >20 fold 1 case, 5-10 fold I case, >20 fold 1 case, >20 fold
1 case, 15-20 fold 1 case, 15-20 fold
I case, >20 fold
aAbnormalities of gene expression are defined as definite membrane staining on immunohistochemistry.EGF RECEPTOR AND C-erbB-2 IN STOMACH CANCER 81
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Figure 1 a, Southern blot analysis of c-erbB-2 and beta actin
genes in gastric adenocarcinomas. Ten micrograms of EcoRI-
digested DNA was electrophoresed in an 0.8% agarose gel and
transferred to a Hybond-N filter and hybridised with a specific
probe, washed under stringent conditions and autoradiographed
against Fuji RX film with intensifying screens at -70°C for 3
days. The upper panel shows the filter hybridised with the c-erbB-
2 probe, and the lower panel shows the same filter after stripping
and rehybrisation with a beta actin probe. Numerals over pairs of
lanes indicate case numbers (so cases 3 and 4 are illustrated in a
and b), T = tumour DNA, N = normal DNA from peripheral
blood. The c-erbB-2 proto-oncogene is amplified 15- to 20-fold in
case 1, and 5- to 10-fold in case 2. b, Southern blot analysis of
EGF receptor and beta actin genes in gastric adenocarcinomas.
The same filter as in a is shown, now hybridised with the EGF
receptor probe (upper panel) or beta actin probe (lower panel)
using the same conditions described in a. The EGF receptor gene
is amplified more than 20-fold in both cases 4 and 5.
Figure 2 a, Strong immunoreactivity for EGF receptor recog-
nised by 12E antiserum on the brush border on the luminal
surface of enterocytes in intestinal metaplasia of the stomach
(right side of figure). The normal columnar epithelial cells of the
gastric pits (left side of figure) shows no immunoreactivity.
(Formalin-fixed, paraffin section stained by avidin-biotin-
peroxidase complex method, haematoxylin counterstain, x 125).
b, Overexpression of the EGF receptor in a well-differentiated
gastric adenocarcinoma of intestinal type. There is a very strong
membrane immunoreactivity in all the tumour cells (avidin-
biotin-peroxidase complex method, haematoxylin counterstain,
x 125).
luminal surface of cells forming tubules and papillary
structures, in the paraffin section. The 14E antibody gave
positive staining in the same cases as the 12E antibody, but it
was weaker and, as noted in frozen sections, it was often
cytoplasmic rather than membrane staining. Thus the 12E
antibody is likely to be the most useful reagent for the
detection of EGF receptor expression in paraffin-embedded
material, but application of the 14E antibody (which recog-
nises a different epitope) in parallel can help to confirm the
specificity of immunoreactivity.
Only in two cases was there simultaneous overexpression
of both proto-oncogenes (we would expect 1.8 cases to show
concurrent overexpression of EGF receptor and c-erbB-2 by
chance on the basis of frequency of each event alone in this
small series). One case was a poorly differentiated diffuse
type cancer with lymph node metastases which had ampli-
fication of the EGF receptor gene and normal copy number
of the c-erbB-2 gene. The other case was a well differentiated
intestinal type cancer with lymph node metastases which had
normal copy number of both genes.
Our results are consistent with the findings of other pub-
lished studies on small series of stomach cancers. One group
has reported two studies (Yasui et al., 1988a, b) in which
they found a low prevalence of overexpression of EGF recep-
tor in early disease (4%) but a much higher occurrence in
advanced disease (35%). Another study reported a high pre-
valence of EGF receptor mRNA expression in malignant vs
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adjacent non-malignant stomach (Bennett et al., 1989). EGF
receptor gene amplification appears to be rare in gastric
adenocarcinomas, one group reporting only 3% of cases
containing additional gene copies (Yoshida et al., 1989; Oda
et al., 1990). c-erbB-2 is overexpressed in 20% of advanced
stomach adenocarcinomas but not in early disease (Yokota et
al., 1986; Fukushige et al., 1986; Yokota et al., 1988; Tal; et
al., 1988; Park et al., 1989; Falck & Gullick, 1989). It has
been reported as more prevalent in tubular adenocarcinomas
than in diffuse cancers. Overexpression is generally a conse-
quence of gene amplification but some overexpressing cases
may possess a normal gene copy number, and it is intriguing
that one group has recently detected overexpression of a
protein that binds to the TATA box of the c-erbB-2 pro-
moter in such a case (Kameda et al., 1990). Unlike breast
cancer, where most tumour cells in a positive tumour uni-
formly overexpress the protein, in stomach cancer the ex-
pression can be patchy or very focal (Falck & Gullick, 1989).
This suggests that overexpression may occur later in the
progression of stomach cancer than in breast cancer. Gene
rearrangement has also been reported at low frequency in
gastric cancer (Park et al., 1989). One study of 260 stomach
cancers reported that c-erbB-2-positive cases behaved more
aggressively and had worse prognosis than negative cases
(Yonemura et al., 1991).
There is evidence that assessment of EGF receptor and
c-erbB-2 abnormalities can be useful indicators of prognosis
in some other human cancers. For instance, poor clinical
outcome has been correlated with amplification and overex-
pression of the c-erbB-2/HER-2/neu oncogene in breast
cancer (Gullick et al., 1991) and ovarian cancer (Slamon et
al., 1989), and of the c-erbB/EGF receptor oncogene in
breast cancer (Sainsbury et al., 1987). In breast cancer, cases
in which there is overexpression of both of these oncogenes
have a worse prognosis than those in which only c-erbB-2 or
the EGF receptor alone is overexpressed (Harris et al., 1989).
We conclude that abnormal expression of the EGF recep-
tor and c-erbB-2 proto-oncogene occurs at a significant fre-
quency in gastric cancer, in the presence or apparent absence
of gene amplification. We report the application of anti-
peptide antibodies which reliably detect such overexpression
in routinely-fixed and paraffin-embedded pathologic material
and which would be suitable for use in the retrospective
analysis of archival material. We suggest that this would be a
particularly worthwhile exercise for gastric cancer because
conventional typing by the Lauren, WHO and other classi-
fications has been largely unhelpful for prediction of prog-
nosis (Morson et al., 1990). An analysis of the expression of
these proto-oncogenes can now be carried out in a larger
retrospective series of gastric cancers for which survival data
is available.
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